For most of the history of spine medicine, chronic back pain that was not coming from a nerve, a facet joint or the sacroiliac joint was attributed to the disc by elimination. Vertebrogenic pain is a more specific answer, and it points somewhere most patients have never heard of: the vertebral endplate.
The endplate is the thin layer of bone and cartilage at the top and bottom of each vertebral body, where the vertebra meets the disc. It carries load, and it is the route through which the disc — which has no blood supply of its own — is nourished by diffusion. It is also innervated, by a nerve that runs into the middle of the vertebral body called the basivertebral nerve.
When an endplate is damaged and inflamed, that nerve carries pain. The pain is felt in the midline of the back, and it comes from bone rather than from disc or joint.
Most axial back pain has no objective imaging signature, which is why so much of spine diagnosis depends on anesthetic blocks. Vertebrogenic pain is different. Inflammatory and fatty changes in the vertebral body adjacent to a damaged endplate are visible on MRI and are classified as Modic changes — Type 1 representing edema and inflammation, Type 2 representing fatty replacement.
According to PubMed, Type 1 and Type 2 Modic changes are described in the clinical literature as objective biomarkers for vertebrogenic pain, and they were the enrollment criterion for the randomized trials of treatment aimed at the basivertebral nerve (Smuck M, et al. Interv Pain Med. 2023;2(2):100256. DOI).
That does not make the MRI the whole diagnosis. Modic changes appear in people without pain too, and the same rule applies here as everywhere else on this site: the finding has to match the story. But it does mean this is one of the few forms of axial back pain where imaging contributes something specific rather than describing your age.
It overlaps with discogenic pain in almost every clinical feature, which is why the MRI signature carries real weight here.
History and examination first, aimed at the flexion-worse, sitting-worse, midline pattern and at the absence of a radicular signature.
MRI, read specifically for endplate change. This is a case where the sequence and the reading matter — Modic changes at L3 to S1 are the finding of interest, and a report focused on disc and canal may mention them in passing or not at all. Our post on what each imaging modality can and cannot tell you covers the general principle.
Excluding the alternatives with blocks. Facet joints by medial branch block, the sacroiliac joint by intra-articular block, a nerve root by selective nerve root block. All performed under image guidance, under local anesthetic, with no sedation — patients are awake, drive themselves home, and resume normal activity, including work, within two to four hours. In a condition whose presentation overlaps heavily with other axial generators, ruling those out is a substantial part of ruling this one in.
The evidence base for treating the basivertebral nerve is stronger than for many interventional pain targets, and it is worth setting out with its limits attached.
According to PubMed, a prospective randomized multicenter trial at 20 US sites enrolled 140 patients with chronic low back pain of at least six months’ duration and Type 1 or Type 2 Modic changes between L3 and S1, randomized 1:1 to radiofrequency ablation of the basivertebral nerve or continued standard care. At the three-month primary endpoint, mean Oswestry Disability Index change was −25.3 points in the ablation arm against −4.4 with standard care, an adjusted difference of 20.9 points. Visual analog pain scores fell 3.46 against 1.02. An independent data management committee halted enrollment early for superiority and offered crossover to the control arm (Khalil JG, et al. Spine J. 2019;19(10):1620-1632. DOI).
Twelve-month results reported a mean 25.7-point ODI reduction and a 3.8 cm VAS reduction from baseline, with 64 percent achieving at least a 50 percent reduction in pain and 29 percent pain free — and, notably, no change in the proportion of patients using opioids in either group (Smuck M, et al. Reg Anesth Pain Med. 2021;46(8):683-693. DOI). At 24 months, ODI had improved 28.5 points and VAS 4.1 cm from baseline, with 72.4 percent reporting at least 50 percent pain reduction and 31 percent pain free (Koreckij T, et al. N Am Spine Soc J. 2021;8:100089. DOI). Pooled three-year data from two prospective studies reported a mean ODI reduction of 31.2 points and no serious device or procedure-related adverse events across the follow-up period (Smuck M, et al. Interv Pain Med. 2023. DOI).
The randomized trial above compared ablation against continued standard care in an open-label design. Patients knew which arm they were in, and there was no sham procedure — which matters more for procedural treatments than for drugs, because the placebo response to a procedure is substantial and well documented. The enrollment was halted early at an interim analysis, and trials stopped early for benefit tend to overestimate effect size. Much of the long-term data comes from single-arm follow-up of the treated group rather than from a maintained comparison.
And, as with nearly all spine trials, enrollment was selective. These studies required a specific MRI biomarker, a minimum symptom duration, and the absence of competing diagnoses. They did not enroll the patients with several pain generators at once, significant metabolic disease and complex medication histories who make up much of a real interventional practice. That is not a criticism of the trials — it is how trials work — but it does mean the reported response rates describe a filtered population and are a starting point for a conversation about your spine rather than a prediction about it.
Conservative and metabolic care. The endplate is the route through which the disc is nourished, and endplate health depends on microvascular function. Glycemic control, inflammatory load, weight and smoking status all act on that mechanism directly — see microvascular dysfunction and chronic pain, medical weight management and lifestyle medicine. Graded activity and load management remain the base of the plan.
Treating the generators that coexist. Most patients with endplate change also have facet, sacroiliac or nerve-root contributions, and treating a confirmed second generator frequently changes a great deal — facet injections and radiofrequency ablation, sacroiliac joint injection, epidural steroid injections.
Neuromodulation for confirmed, persistent axial pain — spinal cord stimulation, trialed before implant.
[[VARIANT A — USE ONLY IF THE OWNER CONFIRMS THE PRACTICE PERFORMS BASIVERTEBRAL NERVE ABLATION]]
Basivertebral nerve ablation. Where the Modic finding, the clinical picture and the exclusion of other generators all agree, radiofrequency ablation of the basivertebral nerve treats the endplate pain directly. Sedation and recovery details for this procedure must be supplied by the practice before this paragraph is written — they are procedure-specific and must not be inferred from any other procedure on this site.
[[VARIANT B — USE IF THE PRACTICE DOES NOT PERFORM IT]]
Basivertebral nerve ablation is the procedure the trials above studied. It is not among the procedures performed at this practice. Where the evaluation here establishes that endplate pain is the dominant generator and that it warrants that treatment, we say so and help you get to a center that offers it — and we continue to treat the coexisting generators and the metabolic drivers, which is work that does not go away either way.
Fusion is not the answer to vertebrogenic pain as such. Eliminating motion at a segment does not address an inflamed endplate and its nerve supply, and it transfers load to adjacent levels. The whole clinical interest in this diagnosis comes from it being a specific, targetable source that does not require fusing anything.
That is a statement about this condition, not about this practice. Dr. Gurpreet Singh Padda, MD, MBA, MHP is a licensed physician and surgeon with surgical privileges, and surgery is performed here where it is indicated.
Surgery enters the conversation when something else is present — nerve compression with a progressive deficit, instability, fracture, infection or tumor. Each of those is a separate diagnosis, and each is assessed on its own terms rather than folded into an explanation for midline back pain.
Deep central back pain, worse with sitting and bending, that has outlasted several rounds of treatment is worth working up specifically rather than continuing to treat generically. We see patients from across St. Louis, Bridgeton, St. Charles and the Illinois Metro East. Call (314) 481-5000 or request an evaluation.
They are changes in the vertebral bone immediately next to a damaged endplate — Type 1 is edema and inflammation, Type 2 is fatty replacement. They are described in the clinical literature as objective biomarkers for vertebrogenic pain and were the enrollment criterion for the randomized trials of endplate-targeted treatment. They are informative, though like every imaging finding they have to match your symptoms. Read more: Basivertebral nerve ablation and vertebrogenic back pain.
The source is different. Disc pain comes from the disc wall, where a tear exposes nerve endings to inflammatory chemistry. Vertebrogenic pain comes from the bony endplate at the top or bottom of the vertebra, carried by the basivertebral nerve. They present almost identically, which is exactly why the MRI signature and the exclusion of other generators do the work. Read more: Back pain with a normal-looking MRI.
Better than for many interventional targets, with real caveats. A randomized multicenter trial reported a 20.9-point advantage in disability score over standard care at three months and was halted early for superiority, and follow-up at two and three years showed sustained improvement with no serious device-related adverse events. But it was open-label with no sham arm, it was stopped early — which tends to overstate effect — and the long-term data come largely from single-arm follow-up. Read more: Basivertebral nerve ablation and vertebrogenic back pain.
Because an epidural treats inflammation around a nerve root, and vertebrogenic pain does not come from a nerve root. A treatment that fails is diagnostic information: it makes a radicular source less likely and moves the other candidates up the list. That is a reason to test differently, not to conclude nothing can be done. Read more: Why pain injections stop working.
No. The blocks used to exclude facet, sacroiliac and nerve-root sources are performed under local anesthetic with no sedation. You stay awake and responsive, which is what makes the test meaningful, and most patients drive themselves home and resume normal activity, including work, within two to four hours. Read more: What to expect at your first appointment.
No, and it is worth being precise. Endplate-targeted treatment addresses the nerve carrying pain from the bone; it does not repair a disc, reverse degeneration or change alignment. What genuinely influences the underlying process is the health of the tissue’s blood supply — glycemic control, inflammatory load, weight and smoking — which is treated here rather than referred elsewhere. Read more: Microvascular dysfunction and chronic pain.
Long symptom duration is the norm in this diagnosis rather than a disqualifier — in the published trials, roughly two thirds to 71 percent of enrolled patients had had back pain for five years or more, and those were the patients who improved. What matters more than duration is whether the source has ever actually been identified. Read more: What waiting for treatment does to your body.
Prefer not to fill in a form?
Same-day and emergency appointments are available.